News

New study shows Hyperbaric Oxygen Therapy (HBOT) improves heart function and cardiac performance

Summary

This study looked at the performance of the heart as they followed 31 patients, each undergoing a course of 60 hyperabric sessions with the goal of improving cognitive performance. Of these 31 patients, 39% were diagnosed with heart disease, 94% suffered from high blood pressure, and 42% had diabetes mellitus. Most importantly, all 31 patients were screened to be asymptomatic, and did not have any symptoms of heart disease (representing the majority of the public). Researchers documented their results by using pre- and post-imaging of the heart through ultrasound (echocardiogram). The results were extremely favorable following the addition of 60 hyperbaric sessions; ejection fraction (EF) of the heart improved, left ventricular and systolic volume decreased. Myocardial performance index [Mpi] improved, left ventricular [LV] global longitudinal strain increased, and apical rotation improved. This study gives hope for those individuals suffering from heart failure and systolic dysfunction and who need to improve their cardiac performance.
Source: Hyperbaric Experts

Abstract

Hyperbaric oxygenation therapy is successfully implemented for the treatment of several disorders. Data on the effect of hyperbaric oxygenation on echocardiographic parameters in asymptomatic patients is limited. The current study sought to evaluate the effect of hyperbaric oxygenation therapy on echocardiographic parameters in asymptomatic patients. Thirty-one consecutive patients underwent a 60-sessions course of hyperbaric oxygenation therapy in an attempt to improve cognitive impairment. In all subjects, echocardiography examination was performed before and after a course of hyperbaric oxygenation therapy. Conventional and speckle tracking imaging parameters were calculated and analyzed. The mean age was 70?±?9.5 years, 28 [90%] were males. History of coronary artery disease was present in 12 [39%]. 94% suffered from hypertension, 42% had diabetes mellitus. Baseline wall motion abnormalities were found in eight patients, however, global ejection fraction was within normal limits. During the study, ejection fraction [EF], increased from 60.71?±?6.02 to 62.29?±?5.19%, p?=?0.02. Left ventricular end systolic volume [LVESV], decreased from 38.08?±?13.30 to 35.39?±?13.32 ml, p?=?0.01. Myocardial performance index [MPi] improved, from 0.29?±?0.07 to 0.26?±?0.08, p?=?0.03. Left ventricular [LV] global longitudinal strain increased from -?19.31?±?3.17% to -?20.16?±?3.34%, p?=?0.036 due to improvement in regional strain in the apical and antero-septal segments. Twist increased from 18.32?±?6.61° to 23.12?±?6.35° p?=?0.01, due to improvement in the apical rotation, from 11.76?±?4.40° to 16.10?±?5.56°, p?=?0.004. Hyperbaric oxygen therapy appears to improve left ventricular function, especially in the apical segments, and is associated with better cardiac performance. If our results are confirmed in further studies, HBOT can be used in many patients with heart failure and systolic dysfunction.

Source: Int J Cardiovasc Imaging, 2020 Jan 17
See: PubMed

Cheryl Tama Oblander joins TheraMind Services, Inc. as Senior Vice-President, Associate General Counsel & Assistant Secretary

Vernon Hills, IL, July 10, 2019 – TheraMind Services, Inc., a leading provider of advanced health care treatment for neurological and behavioral disorders, is pleased to announce that Cheryl Tama Oblander, J.D., MT (ASCP) has joined their Executive Team as Senior Vice-President, Associate General Counsel & Assistant Secretary, overseeing the company’s legal functions from clinical compliance to business development.

“Cheryl’s experience spanning clinical and legal leadership is uniquely suited to our mission to improve the lives of patients by offering the most advanced healthcare alternatives for individuals dealing with anxiety, depression, and other mood disorders,” said TheraMind Services, Inc. President, Mark Heatwole. “Cheryl’s expertise benefits our clients and the outstanding clinical services our team is able to provide, as we expand the company to meet the demand from consumers and health care providers for access to rapidly increasing options for proven effective treatments.”

Prior to joining TheraMind, Cheryl was a partner and practiced law with two large international law firms, representing clients in a wide variety of industries, including health care providers, pharmaceuticals and medical device manufacturers. Her practice areas included federal and state employment law, employee benefits, fiduciary duties, trade secrets, restrictive covenants, executive employment and compensation agreements, hiring, discipline and terminations, employment policies, legal compliance, internal investigations and employment aspects of mergers, acquisitions and reorganizations. Cheryl was lead counsel of record in more than 100 cases, including every level of litigation from single-plaintiff matters to large scale complex and class actions. Her practice spanned the country and she is admitted to courts in multiple jurisdictions, including the United States Supreme Court.

With Theramind, Cheryl combines her many years of legal practice with her earlier health care experience. Prior to attending Loyola University Chicago School of Law, she had a decade of experience providing direct patient services. She had trained at Michael Reese Hospital and Medical Center in its Medical Technology Program, received her Medical Technology license (American Society for Clinical Pathology), and became Senior Medical Technologist in the Department of Biochemistry. In that role, she was responsible for routine and emergency analyses of patient specimens for complex chemical and biological components, performed advanced trouble shooting for state of the art analytical equipment, evaluated test results, developed and modified clinical laboratory procedures, and established and monitored programs to ensure the accuracy of test results and to maintain compliance with all laboratory accrediting requirements.

“I am excited to join TheraMind Services, Inc., where I will combine my legal and medical experiences working with an excellent team to successfully navigate the landscape of health care advancements, compliance and coverage in this important and rapidly expanding field,” said Cheryl.

About TheraMind Services, Inc.

TheraMind Services, Inc. is committed to improving the lives of patients by providing physicians with the most advanced therapeutic, non-drug alternatives for treating a broad variety of neurological and behavioral disorders. Our doctors successfully treat patients suffering from treatment-resistant depression (TRD), Major Depressive Disorder (MDD), Anxiety Disorder, Post-Traumatic Stress Disorder (PTSD), Bipolar Disorder, Obsessive Compulsive Disorder (OCD) and other mood disorders. The Center also routinely treats patients suffering from a variety of neurological disorders including Chronic Pain, Fibromyalgia, Migraines, Tinnitus, Stroke-related disorders, Concussion and TBI, and others.

We employ advanced diagnostic technologies such as fMRI and genetic testing to assist our physicians and referring medical professionals in assessing patient needs. Our highly-trained staff members are committed to providing outstanding supporting services to referring medical professionals, their patients and the patients’ family members. For more information about TheraMind Services, Inc. and our TheraMind Centers, please visit https://tmsmind.com/.

TheraMind Services, Inc. opens new outpatient facility in Chicago

New TheraMind© Center of Chicago located in landmark Willoughby Tower

Chicago, IL, July 10, 2019 — TheraMind Services, Inc., a leading provider of advanced health care treatments for neurological and behavioral disorders, is pleased to announce the opening of their new Chicago outpatient treatment center, which is centrally located in the Historic Michigan Avenue District, at 8 S. Michigan Avenue in the landmark Willoughby Tower. The 36-story Willoughby Tower, located just across from Grant Park and “The Bean,” is home to an array of renowned regional healthcare and nonprofit organizations.

Medical direction at the new Center is provided by Dr. Dawna Gutzmann, a graduate of Northwestern University’s Feinberg School of Medicine, who has over 20 years of experience treating patients with mood disorders and who has been affiliated with TheraMind Services, Inc. at the TheraMind Center of Skokie since 2014.

Treatment options available at the new TheraMind Center of Chicago include, in addition to traditional psychiatric services, Transcranial Magnetic Stimulation (TMS), a non-invasive, FDA-approved, high tech therapy which uses rapid magnetic pulses to stimulate nerve cells in the area of the brain known to control mood. TMS treatments are outpatient procedures requiring no anesthesia or sedation and are covered by most healthcare insurers and Medicare for depression.

“Our expansion into major cities like Chicago is being driven by demand for non-drug alternatives for individuals dealing with anxiety, depression, and other mood disorders,” said TheraMind Services, Inc. President Mark Heatwole. “TMS has been demonstrated to be a highly effective therapy for treating patients suffering from depression which is not adequately managed by antidepressants. It’s not surprising, therefore, that patients are seeking the innovative medical solutions TheraMind is known to deliver. In the greater Chicago area, we serve the north and northwestern communities through our Centers in Skokie and Vernon Hills and we are delighted to now be able to offer our most advanced behavioral therapies to the downtown Chicago community.”

Recent TMS and HBOT Studies June 2019 Update

The pace of studies being published on the effects of TMS continues to climb, recently reported to be more than 25 per week.

Two new and notable studies have confirmed the positive effect of TMS on cognitive performance and its potential implications for persons suffering from dementia/Alzheimer’s Disease. Also listed below, notable remarks on TMS therapy as a prophylactic treatment for migraine, and a study exploring Hyperbaric Oxygen Therapy (HBOT) in men’s health.


TMS and Cognitive Performance

Duke University news: May 15, 2019
Published in the Journal PloS One. Researchers in Duke University’s Department of Neurology found that both healthy older (18 participants) as well as healthy younger adults (29 participants) who received TMS therapy performed working memory tasks better than those study participants who received a placebo. The study utilized functional Magnet Resonance Imaging (fMRI) to determine stimulation targets for LDLPFC 5Hz stimulation.

Online repetitive transcranial magnetic stimulation during working memory in younger and older adults: A randomized within-subject comparison L. Beynel , S. W. Davis , C. A. Crowell, S. A. Hilbig, W. Lim, D. Nguyen, H. Palmer, A. Brito, A. V. Peterchev , B. Luber, S. H. Lisanby, R. Cabeza , L. G. Appelbaum; Published: March 22, 2019

Study: https://doi.org/10.1371/journal.pone.0213707 
Article: www.devdiscourse.com/article/international/527727

Performed at Northwestern University, published in the Journal Neurology: fMRI-guided TMS therapy was used to stimulate the patients’ hippocampus through targeting of the parietal lobe, a brain structure with known synchronicity with the hippocampus. Sixteen (16) adults aged between 64 and 80 who exhibited normal age-related memory deficits were treated with TMS for 20 minutes per day for five (5) consecutive days. After 24 hours had elapsed following the patients’ last treatment, the study participants were retested and performed at the same cognitive level as the younger control group. Notably, a second group of older adults who received a placebo instead of TMS therapy did not show an improvement in memory function.

Network-targeted stimulation engages neurobehavioral hallmarks of age-related memory decline Aneesha S. Nilakantan, M.-Marsel Mesulam, Sandra Weintraub, Erica L. Karp, Stephen VanHaerents, Joel L. VossNeurology May 2019, 92 (20) e2349-e2354; DOI:10.1212/WNL.0000000000007502

https://n.neurology.org/content/92/20/e2349


TMS as Prophylactic Option for Migraine Sufferers

TMS has been FDA-approved since 2013 to treat major depression and migraines. In an additional TMS-related development, Doctor Michael Cutrer, a neurologist at the Mayo Clinic, told the audience at the April 2019 American College of Physicians Internal Medicine Meeting in Philadelphia, that TMS therapy was effective in stopping the aura in Migraines and a reasonable alternative prophylactic option for migraine sufferers who feared repeated attacks.

https://www.healio.com/family-medicine/pain-management/news/online/%7B05772911-c028-4d22-9a06-58fac8bd07dd%7D/differentiating-between-migraine-treatments


HBOT in Men’s Health

Hyperbaric Oxygen Therapy (HBOT) has also received a spate of new positive clinical research outcomes.

Most notably: On April 30, 2019 an article appeared in PubMed from the Med Gas Res. 2018 April 18:8(1) 29-33 entitled: “Clinical utility of hyperbaric oxygen therapy in genitourinary medicine” by Gandhi, J. et al. The authors noted that HBOT was making gradual strides in genitourinary medicine “due to its low risk and likeliness to achieve favorable results”. The authors also pointed success with HBOT in treating radiation cystitis, erectile dysfunction secondary to urethroplasty, blood testosterone and other indications.

Between 2016 and today there have been a number of clinical studies that have concluded that HBOT has a positive impact on Erectile Dysfunction although there have been some studies that found the improvement in ED without being able to determine an increase in serum testosterone levels in study participants.


Is there a study you would like to bring to our attention? Please contact us today.

Take the first step

Contact us to schedule your FREE consultation today.

TheraMind Center of Santa Barbara

351 Hitchcock Way, Ste. B170
Santa Barbara, CA 93105
Phone: (805) 845-4455 | Fax: (805) 845-9820